EsoGuard Methylation Assay for Barrett’s Esophagus
Esophageal adenocarcinoma is a serious cancer with only a 20% survival rate at 5 years. The only known antecedent of esophageal adenocarcinoma is Barrett’s esophagus, a condition where the normal squamous lining of the lower esophagus is replaced by columnar gastrointestinal epithelium. Patients with Barrett’s esophagus are at high risk of developing esophageal adenocarcinoma. The exact mechanism behind the causation of Barrett’s esophagus is unknown but attributed to gastrointestinal reflux (heartburn). Most cases of Barrett’s esophagus remain undiagnosed or diagnosed late when a metaplastic transformation has occurred.
EsoGuard Methylation Assay is a molecular technique used for the screening of Barrett’s esophagus and predicts the risk of esophageal adenocarcinoma based on esophogeal cells collected by a non-endoscopic method. The assay employs aberrant DNA methylation patterns as molecular markers for Barrett’s esophagus. Vimentin and CyclinA1 methylation at 31 different sites of the DNA is screened via next-generation sequencing. Studies in patients with GERD symptoms indicate that this testing is an acceptable alternative to endoscopic examination and biopsy. If positive the patient, should undergo endoscopy with multiple biopsies to confirm the diagnosis of BE and evaluate for the presence of carcinoma.
- Useful in screening individuals for Barrett’s esophagus
- Helpful in monitoring patients with gastrointestinal reflux disease
Negative
Specimen: Esophageal brushings obtained via EsoCheck cell collection device
EsoCheck cell collection device: Consists of a swallowable catheter with a deflated balloon that is inflated in the stomach. Balloon consists of ridges that collect cells from the gastroesophageal junction when the catheter is pulled out. Cells are then collected in a vial.
- Sci Transl Med. 2018 Jan 17;10(424):eaao5848. [PMID: 29343623]
- JAMA. 2013 Aug 14;310(6):627-36. [PMID: 23942681]
- Clin Cancer Res. 2019 Apr 1;25(7):2127-2135. [PMID: 30670490]
- Curr Gastroenterol Rep. 2019 Jul 25;21(9):42. [PMID: 31346777]
- Gastroenterol Hepatol (N Y). 2022 May;18(5):272-275. [PMID: 36397757]